PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.

Angiogenesis Immune checkpoints PD-L1 Papillary renal cell carcinoma

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
13 May 2024
Historique:
received: 05 03 2024
revised: 02 05 2024
accepted: 09 05 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 15 5 2024
Statut: aheadofprint

Résumé

Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors (ICI) are a promising option. We aimed to study the immune landscape of metastatic pRCC, and its interactions with angiogenesis pathways, to search for potential therapeutic targets. The expression of immune markers (PD-L1, PD-1, PD-L2, LAG-3) and angiogenic pathways (CAIX, c-MET), was analyzed by immunohistochemistry on 68 metastatic pRCC retrieved from a retrospective multicenter GETUG cohort. Our primary endpoint was to estimate the prevalence of PD-L1 expression and its prognostic impact in metastatic pRCC. Secondary endpoints included the evaluation of other immune markers (PD-1, PD-L2, and LAG-3) and their association with PD-L1. We also assessed angiogenic markers and their association with PD-L1. Overall, 27.9 % of tumors were PD-L1 positive. PD-L2 was more frequently expressed (45.6 %), PD-1 and LAG-3 were positive in 17.6 % and 19.1 % respectively. None of these markers was correlated with PD-L1 expression. 66 % (45/68) expressed at least one immune marker, and 43 % (29/68) were "double-positive", as they expressed both immune and angiogenic markers. OS was significantly shorter for patients with PD-L1 positive pRCC. A multivariate analysis confirmed a significant association between PD-L1 expression and shorter overall survival (HR = 4.0, p = 0.01). These results reinforce clinical data on the expected benefit of ICI in metastatic pRCC treatment, as PD-L1 expression is a factor of poor prognosis in this multicenter cohort.

Identifiants

pubmed: 38749111
pii: S0959-8049(24)00777-9
doi: 10.1016/j.ejca.2024.114121
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114121

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jérémie Naffrichoux (J)

Department of Medical Oncology, University Hospital, Tours, France.

Pierre Poupin (P)

INSERM CIC 1415, University Hospital, Tours, France.

William Pouillot (W)

Department of Pathology, University Hospital, Tours, France.

Claude Linassier (C)

Department of Medical Oncology, University Hospital, Tours, France.

Nathalie Rioux-Leclercq (N)

Department of Pathology, Pontchaillou University Hospital, Rennes, France.

Manon De Vries-Brilland (M)

Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Angers, France.

Loïc Mourey (L)

Department of Medical Oncology, IUCT Oncopole, Toulouse, France.

Brigitte Laguerre (B)

Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France.

Stéphane Oudard (S)

Department of Medical Oncology, Georges Pompidou Hospital, University Paris Cité, Paris, France.

Marine Gross-Goupil (M)

Department of Medical Oncology, Saint-André University Hospital, Bordeaux, France.

Coralie Mousset (C)

Department of Pathology, University Hospital, Tours, France.

Gwenaelle Gravis (G)

Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.

Frédéric Rolland (F)

Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint Herblain, France.

Laura Moise (L)

Department of Medical Oncology, Centre François Baclesse, Caen, France.

Sheik Emambux (S)

Department of Medical Oncology, La Milétrie University Hospital, Poitiers, France.

Cécile Vassal (C)

Department of Medical Oncology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.

Sylvie Zanetta (S)

Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Nicolas Penel (N)

Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France.

Laurence Albiges (L)

Department of Medical Oncology, Gustave Roussy, Villejuif, France.

Gaëlle Fromont (G)

Department of Pathology, University Hospital, Tours, France; INSERM UMR 1069, N2COx, Tours University, Tours, France.

Mathilde Cancel (M)

Department of Medical Oncology, University Hospital, Tours, France; INSERM UMR 1069, N2COx, Tours University, Tours, France. Electronic address: m.cancel@chu-tours.fr.

Classifications MeSH